Shijiazhuang Yiling Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Shijiazhuang Yiling Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Shijiazhuang Yiling Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Shijiazhuang Yiling Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Shijiazhuang Yiling Pharmaceutical Co Ltd (Yiling Pharmaceutical) is a pharmaceutical company that develops and manufactures traditional Chinese medicines and consumer health products. The company provides patent Chinese herbal drugs, dietary supplements, health drinks, formula granules, disinfection products, and personal protective equipment. Its products address conditions across respiratory health, cardiovascular disease, diabetes mellitus, oncology, urologic disease, sleep improvement, and anti-aging. The company performs clinical trials across cardio-cerebrovascular, digestive, endocrine, immunological, and respiratory indications. It operates through offices and agents across China, Europe, Africa, the Middle East, North America, and South America. Yiling Pharmaceutical is headquartered in Shijiazhuang, Hebei, China.
Headquarters
China
Address
No. 238, Tianshan Avenue, High-Tech Industrial Development Zone, Shijiazhuang, Hebei, 050035
Website
www.yiling.cn
Telephone
86 311 85901311
No of Employees
11,343
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002603 (SHE)
Revenue (2024)
$1.1B
20.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
277.6%
(2024 vs 2023)
Market Cap*
$3.8B
Net Profit Margin (2024)
XYZ
247.8%
(2024 vs 2023)
* As of and is in US$
Shijiazhuang Yiling Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Patent TCM |
| Respiratory Health Products |
| Cardiovascular Disease Products |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In August, the company and Ant Group Healthcare entered into a cooperation agreement to develop a domestic digital content ecosystem for pharmaceuticals and healthcare. |
| 2024 | Contracts/Agreements | In October, the company signed a partnership with Hangzhou Changxi Pharmaceutical for research and development of innovative drugs to treat patients with lung and related diseases. |
| 2023 | Contracts/Agreements | In May, the company signed an agreement with JD Health to offer consumers more personalized and professional health management services through online doctor consultation and health management. |
Competitor Comparison
| Key Parameters | Shijiazhuang Yiling Pharmaceutical Co Ltd | China Resources Jiangzhong Pharmaceutical Co Ltd | Guizhou Bailing Group Pharmaceutical Co Ltd | Aurisco Pharmaceutical Co Ltd | Xiangxue Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shijiazhuang | Nanchang | Anshun | Taizhou | Guangzhou |
| State/Province | Hebei | Jiangxi | Guizhou | Zhejiang | Guangdong |
| No. of Employees | 11,343 | 4,352 | 5,715 | 2,026 | 2,662 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wu Xiangjun | Chairman | Executive Board | 2023 | 51 |
| Li Chenguang | Director; Chief Financial Officer | Executive Board | 2018 | 53 |
| Zhang Keyuan | Director; Deputy General Manager | Executive Board | 2019 | 59 |
| Wu Rui | Director; Secretary | Executive Board | 2016 | 46 |
| Zhang Xiaojun | Deputy General Manager | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer